Is Gilead Sciences Stock a Buy?
Gilead Sciences (NASDAQ: GILD) has been at the forefront of the coronavirus treatment space since the early days of the pandemic. During this past spring and early summer, the company donated almost a million doses of its antiviral medication, remdesivir, to the U.S. government in hopes that it would be useful against the coronavirus. It was found to have moderate benefits, and in late June, CEO and chairman Daniel O'Day announced the price going forward.
The company will charge developed countries $2,340 per treatment course of remdesivir, while private insurers in the U.S. will be charged $3,120 per course. Considering that Gilead intends to produce more than 2 million courses of the antiviral drug before the year is out and millions more next year, remdesivir has significant blockbuster potential.
Gilead Sciences hasn't been immune to the ups and downs of the coronavirus stock market. To be fair, neither have most companies. But is Gilead Sciences a stock you can buy and hold in the current recession and beyond?
Source Fool.com
